Atlas Trials

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Clinical trial NCT05786430 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05786430
Sponsor
Yonsei University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2023-04-07
Primary completion
2026-08-01
Enrollment
87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.